Although desmoid tumors do not metastasize, they can be associated with recurrence rates of up to 77% after surgical resection. 6,9 Desmoid tumor experts and treatment guidelines now recommend ...
The FDA has expanded the label for oral semaglutide (Rybelsus; Novo Nordisk) tablets 7 mg and 14 mg to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who ...
An innovative new pill could soon offer a new and affordable weight management treatment, following a successful clinical ...
Geographic atrophy due to age-related macular degeneration (AMD) is the leading cause of irreversible blindness and affects more than 5 million persons worldwide. No therapies to restore vision in ...
Learn how accelerating drug discovery is reshaping the pathway from lab findings to effective therapies with real-world data.
As Novartis moves ahead plans to expand Pluvicto's use based on the PSMAddition trial, experts urge for greater use of ...
Semaglutide reduces cardiovascular events by 23% and direct heart disease death risk by 26% compared to dulaglutide in older ...
PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic ...
Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated ...
The Brighterside of News on MSN
New AI model revolutionizes medical imaging with 90% less computing power
When doctors review brain scans, each detail of the picture—each pixel or voxel—must be painstakingly labeled. The cerebral ...
The White House has raised concerns around women’s health, but R&D on pregnant and breastfeeding women is still lacking.
For years, MASH was where drug development dreams went to die. | After Rezdiffra’s approval and Wegovy’s label expansion, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback